Efficacy and Safety of Glofitamab Plus Polatuzumab Vedotin in Relapsed/Refractory Large B-Cell Lymphoma Including High-Grade B-Cell Lymphoma: Results From a Phase Ib/II Trial.

Journal:

Journal of Clinical Oncology

Published:

2025-10-21

DOI:

10.1200/jco-25-00992

Affiliations:

22

Authors:

20

Go to article

Institutions	Authors	Share
F. Hoffmann-La Roche Ltd., Switzerland	2.000000	0.10
Roche Products Limited, United Kingdom (UK)	2.000000	0.10
IRCCS Istituto Nazionale Tumori IRCCS-Fondazione G. Pascale, Italy	1.000000	0.05
Biomedical Research Institute (INCLIVA), Spain	1.000000	0.05
Genentech, Inc., United States of America (USA)	1.000000	0.05
Aarhus University Hospital, Denmark	1.000000	0.05
Novant Health, United States of America (USA)	1.000000	0.05
Institute of Biomedical Research in Malaga (IBIMA), Spain	1.000000	0.05
Vall d'Hebron University Hospital (HUVH), ICS, Spain	1.000000	0.05
Azienda Ospedaliera Papa Giovanni XXIII, Italy	1.000000	0.05
Odense University Hospital (OUH), Denmark	1.000000	0.05
Hospital Universitario Fundación Jiménez Díaz (FJD), UAM, Spain	1.000000	0.05
Bellvitge Biomedical Research Institute (IDIBELL), Spain	1.000000	0.05
Roche R&D Center (China) Ltd., China	1.000000	0.05
Chaim Sheba Medical Center at Tel HaShomer, Israel	0.500000	0.03
Tel Aviv University (TAU), Israel	0.500000	0.03
Sant'Orsola Malpighi Hospital, Italy	0.500000	0.03
IRCCS National Cancer Institute (INT) Milan, Italy	0.500000	0.03
University of Milan (UNIMI), Italy	0.500000	0.03
Rigshospitalet, Denmark	0.500000	0.03
University of Copenhagen (UCPH), Denmark	0.500000	0.03
University of Bologna (UNIBO), Italy	0.500000	0.03

Interested in Cardiovascular Medicine and Haematology?